Levosimendan: A new option in acute septic cardiac failure? [2]

EMA - Emergency Medicine Australasia

Volumn 19, Issue 2, 2007, Pages 177-

  Powell, Bruce Patrick ^a   De Keulenaer, Bart ^a  

^a Intensive Care Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; INTERLEUKIN 1BETA; LEVOSIMENDAN; TROPONIN C; TUMOR NECROSIS FACTOR ALPHA;

BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARDIOGENIC SHOCK; HEART FAILURE; HEART VENTRICLE CONTRACTILITY; HUMAN; HYPOTENSION; LETTER; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SEPSIS; TACHYCARDIA;

ACUTE DISEASE; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PYRIDAZINES; SEPSIS;

EID: 34247279115     PISSN: 17426731     EISSN: 17426723     Source Type: Journal    
DOI: 10.1111/j.1742-6723.2007.00952.x     Document Type: Letter

References (5)

1. Dellinger R., Carlet J, Masur H. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 2004; 32: 858-73.
2. Kumar A, Thota V, Dee L et al. Tumour necrosis factor-alpha and interleukin 1-beta are responsible for depression of in vitro myocardial cell contractility induced by serum from humans with septic shock. J. Exp. Med. 1996; 183: 949-58.
3. Yokoyama T, Vaca L, Rossen RD et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in adult mammalian heart. J. Clin. Invest. 1993; 92: 2303-12.
4. Morelli A, Teboul J-L, Maggiore SM et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit. Care Med. 2006; 34: 2287-93.
5. Morelli A, De Castro S, Teboul J-L et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005; 31: 638-44.